7/21/2006 | BT | Market Commentary: Amgen stronger; ReGen cheered; Cleveland BioLabs debuts lower; Amylin, Nektar weaker
|
7/20/2006 | BT | Market Commentary: Amgen weakens; Gilead off 3%; Alfacell falls 30%; Nektar up; Accentia lower; Connetics lifted
|
3/30/2006 | BT | Amgen, Abgenix complete BLA for FDA approval of panitumumab for colorectal cancer
|
2/22/2006 | BT | Abgenix at hold by Jefferies
|
1/20/2006 | CV | Market Commentary: Hutchinson hovers around par; Schlumberger surges; Ford sags, Oscient tumbles
|
12/16/2005 | BT | Market Commentary: Amgen, Abgenix easier; takeover talk fuels rise in Imclone, several other biotechs; Kos slide continues
|
12/15/2005 | BT | Merrill changes Abgenix to no rating
|
12/15/2005 | BT | Abgenix price target raised to $22 by Jefferies
|
12/15/2005 | BT | Market Commentary: OSI Pharma on deck; Oxigene off on steep discount; BioCryst slips on PIPE; Somaxon sinks on debut
|
12/15/2005 | CV | Market Commentary: ON Semi, OSI Pharma at bat; Entergy goes to 50.5 bid; Intel steady; Abgenix issues climb
|
12/14/2005 | BT | Amgen to acquire Abgenix for $2.2 billion
|
12/14/2005 | BT | Market Commentary: BB Biotech deal on tap Friday; Amgen, Abgenix ink long-awaited merger; Oxigene seen on deck
|
12/14/2005 | CV | Market Commentary: Intel, Ceradyne trade higher; United Dominion re-offered; Entergy up in gray; OSI launches $100 million
|
12/5/2005 | BT | Market Commentary: Noven soars on ADHD patch news; Ligand bounces on board expansion; Progenics off sharply
|
12/2/2005 | BT | Market Commentary: Inspire sinks; Abgenix off, short interest on the rise; ViroPharma up; Nucryst IPO added to calendar
|
11/10/2005 | BT | Market Commentary: King Pharma off, Pain increases; ViroPharma falls on generic risk; Eyetech, OSI seesaw on merger
|
11/8/2005 | BT | Merrill Lynch reiterates Abgenix at buy
|
11/8/2005 | BT | Market Commentary: Pharmaxis off on stock dilution; Patheon refinancing bank paper; Serono up on sale news
|
11/4/2005 | BT | Jefferies ups Abgenix price target to $13
|
11/4/2005 | BT | Merrill Lynch reiterates Abgenix's buy rating
|
11/3/2005 | BT | Amgen, Abgenix panitumumab colorectal cancer study shows positive results
|
11/3/2005 | BT | Merrill reiterates Abgenix at buy
|
11/3/2005 | BT | Market Commentary: Abgenix, Amgen stocks take off on successful phase III study; Merck wins legal battle over Vioxx
|
11/3/2005 | CV | Market Commentary: Chesapeake, Qwest trade higher; Abgenix, Amgen rise, but ImClone lower; SFBC plunges
|
11/2/2005 | BT | Merrill reiterates Abgenix buy
|
10/26/2005 | BT | Merrill reiterates Abgenix buy rating
|
10/26/2005 | BT | Jefferies reiterates Abgenix at hold
|
10/20/2005 | BT | Market Commentary: Predix IPO put on hold; Amgen spiral continues; Abgenix climbs; generics off despite Tamiflu talks
|
10/19/2005 | BT | Merrill Lynch maintains Abgenix at buy
|
10/18/2005 | BT | Jefferies maintains Abgenix cautious stance, hold
|
10/18/2005 | BT | Market Commentary: Amgen up; Abgenix, Cell Genesys lower; Chiron drops; Gilead sold on nice quarter; Genzyme seesaws
|
10/11/2005 | BT | Market Commentary: OSI Pharma off as Genentech reports Tarceva weakness; ImClone up at Abgenix expense
|
9/14/2005 | BT | Market Commentary: Progenics off on spot sale; profits taken on Celgene rise; Cubist off; Access dives on bankruptcy fears
|
9/2/2005 | BT | Market Commentary: Cell Therapeutics plunges on auditor departure; Amylin shares off on profit taking; Watson off
|
9/1/2005 | BT | Market Commentary: Chiron shares, convertibles gain on Novartis bid; Par Pharma up 1%; Cephalon up 5%, Abgenix up 9%
|
8/15/2005 | BT | Market Commentary: Cita defers IPO plans for merger talks; Kosan dives on trial delays; Incyte, Abgenix buyers emerge
|
8/15/2005 | CV | Market Commentary: Agilent issue gains to par on call; Fleetwood in for bumpy ride; Calpine issues up despite warning
|
8/1/2005 | BT | Market Commentary: Anadys, Ariad, Nastech offerings join ZymoGenetics for this week; Amgen, Abgenix up on fast track
|
8/1/2005 | CV | Market Commentary: CommScope jumps, but Isolagen tumbles amid slightly weaker convertibles market
|
7/28/2005 | BT | Abgenix price target upped by Jefferies
|
7/27/2005 | BT | Abgenix estimates upped by Merrill Lynch
|
7/20/2005 | BT | Market Commentary: Accentia, Adams IPOs on deck as biotech index surges; BioMarin, Keryx bode well; Amgen rockets
|
7/15/2005 | BT | Market Commentary: Accentia IPO pushed back; Keryx zooms; Rigel off; Adherex gets big partner; Abgenix seen in play
|
7/1/2005 | BT | Market Commentary: Altana crushed by Pfizer news; Cubist, Corixa rise in thin market, Millennium off; Cephalon higher
|
6/29/2005 | BT | Abgenix reiterated by Merrill at buy
|
6/28/2005 | BT | Market Commentary: Lonza, CV Therapeutics converts on tap; Cubist zooms; Abgenix up on belt tightening; Wyeth a boost
|
6/20/2005 | BT | Market Commentary: HemoSense cuts IPO range; Impax labs, Xoma gain on credit fronts; ImClone up on drug plans
|
6/17/2005 | BT | LifeCell cut to hold by Wells Fargo
|
12/22/2004 | CV | Abgenix greenshoe exercised, raising convertibles to $300 million
|
12/17/2004 | CV | Market Commentary: IVAX reoffered at 98.5; BearingPoint up to 101.25; Charter up on M&A talk; PSEG soars on buyout buzz
|
12/16/2004 | CV | New Issue: Abgenix sells upsized $225 million convertible to yield 1.75%, up 30%
|
12/16/2004 | CV | Market Commentary: Abgenix goes to 104; NRG climbs to 106.5; Gateway, BearingPoint up when-issued
|
12/15/2004 | CV | Market Commentary: Abgenix bid at 102.5 in gray market; NRG goes to 105; Gateway, Dover, BearingPoint rush market
|
12/14/2004 | CV | Abgenix $150 million convertible talked to yield 1.75%-2.25%, up 25%-30%
|
12/14/2004 | CV | Market Commentary: NRG trades up 3.5 points in gray market, terms tightened; Abgenix launches new deal
|
12/14/2004 | CV | Abgenix to retire some 2007 convertibles with $150 million convertible sale proceeds
|
4/27/2004 | CV | Market Commentary: Reebok bounces to 102.25; OSI Pharma, cancer issues snap back; three deals at bat
|
4/26/2004 | CV | Market Commentary: OSI Pharma skyrockets amid buying frenzy as stock shoots up 139%; 4 new deals emerge
|
11/10/2003 | CV | Market Commentary: Biotech paper grabs attention as yield-hungry investors invade market
|
1/30/2003 | CV | Deutsche sees 9 biotech issues highly probable for distressed exchange
|
9/24/2002 | CV | Market Commentary: Ballooning credit spreads weigh but drugmakers gain on buying
|
9/4/2002 | CV | Market Commentary: Market tone improves but still patchy; Symantec, Calpine gain
|
7/10/2002 | CV | Market Commentary: Stock plunge, earnings worries sideline players, pressure prices
|
7/8/2002 | CV | Market Commentary: Market idled by stock slump, summer, lack of new issues
|
6/12/2002 | CV | Deutsche on biopharma: buy Inhale, Cell Therapeutics; hold Abgenix, Alexion; sell Vertex, ISIS
|
5/17/2002 | CV | Market Commentary: LifePoint gains in hungry market; El Paso drops on "bad" news
|
5/14/2002 | CV | Market Commentary: Broadbased gains as better retail sales confirm recovery signs
|
4/5/2002 | CV | Market Commentary: Adelphia gains on hiring advisors; Getty Images soars on EPS revision; Genentech falls
|
3/4/2002 | CV | Market Commentary: Convertibles buyers chase paper higher; new GM deal up sharply
|
3/1/2002 | CV | Market Commentary: Convertibles bounce but new paper lags
|
2/28/2002 | CV | Market Commentary: Convertibles choppy, lower but GM deal upped to $3.25 billion
|
2/27/2002 | CV | New Issue: Abgenix $200 million convertibles yield 3.5%, up 15%
|
2/27/2002 | CV | Market Commentary: Convertibles mixed, new deals at center stage
|
2/26/2002 | CV | Market Commentary: Convertibles mixed, players welcome slew of new deals
|
2/26/2002 | CV | Abgenix $200 million convertibles talked at 3.25-3.75% yield, up 15-20%
|